Concepedia

Neutral 5-substituted 4-anilinoquinazolines as potent, orally active inhibitors of erbB2 receptor tyrosine kinase

Peter Ballard, Bernard Barlaam, Robert H. Bradbury, Allan Dishington, Laurent Hennequin, D. Mark Hickinson, Ian Hollingsworth, Jason G. Kettle, Teresa Klinowska, Donald Ogilvie,

Bioorganic & Medicinal Chemistry Letters · 2007 · 25 citations · 23 references

DOIFull text

Open access

Concepts

References

23

A Unique Structure for Epidermal Growth Factor Receptor Bound to GW572016 (Lapatinib)

Edgar R. Wood, Anne T. Truesdale, Octerloney B. McDonald et al. · Cancer Research · 2004 · 1.1K citations · Full text

, , +14

Recombinant humanized anti-HER2 antibody (Herceptin) enhances the antitumor activity of paclitaxel and doxorubicin against HER2/neu overexpressing human breast cancer xenografts.

José Baselga, Larry Norton, Joan Albanell et al. · PubMed · 1998 · 1K citations

, , +15

BindingDB Entry 50022499: ZD1839 (Iressa): an orally active inhibitor of epidermal growth factor signaling with potential for cancer therapy.

PubMed · 2025 · 933 citations · Full text

, , +12

Predictive Pharmacokinetic-Pharmacodynamic Modeling of Tumor Growth Kinetics in Xenograft Models after Administration of Anticancer Agents

Monica Simeoni, Paolo Magni, Cristiano Cammia et al. · Cancer Research · 2004 · 499 citations · Full text

, , +16

<i>N</i>-(5-Chloro-1,3-benzodioxol-4-yl)-7-[2-(4-methylpiperazin-1-yl)ethoxy]-5- (tetrahydro-2<i>H</i>-pyran-4-yloxy)quinazolin-4-amine, a Novel, Highly Selective, Orally Available, Dual-Specific c-Src/Abl Kinase Inhibitor

Laurent Hennequin, J M Allen, J. Breed et al. · Journal of Medicinal Chemistry · 2006 · 367 citations · Full text

, , +15